Kornimate/medical-research-clean huggingface dataset:
the efficiency of cams (chinese academy of medical sciences)-2016 trial for pediatric acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to evaluate that whether the aml (acute myeloid leukemia)-cams (chinese academy of medical sciences)-2016 regimen, includes risk-stratified therapy and the use of dasatinib in cbf (core binding factor)-aml, can improve the outcome in childhood aml.

primary aml includes cbf(core binding factor)-aml and non-cbf-aml. after the second course of therapy, cbf-aml are stratified into two risk groups: low-risk children are defined as those with cr after mae or cag, high-risk children are those with cr after consolidation course 1 or iae. non-cbf-aml patients in remission are stratified into three risk groups: low-risk children are defined as those with t(1；11)(q21；q23) , gata1, npm1/idh1/idh2 without flt3/itd,or an age younger than 2 years without high-risk factors; high-risk children are those with cr after consolidation course 1 or iae or with abnormalities of monosomy 7, 5q- , t(16;21), t(9;22) (philadelphia chromosome \[ph1\]), flt3/itd,-17/tp53, rpn1-mecom, runx1-evi1, mlf1-npm1, prdm16-rpn1, dek-nup214, etv6(tel)-hlxb9(mnx1), nup98-nsd1; intermediate-risk children are those who were not in either a low-risk or high-risk group.low-risk children were treated only with chemotherapy, regardless the availability of a suitable hsct donor. all high-risk children were allocated to allo-hematopoietic stem cell transplantation (hsct) in the first remission, including unrelated bone marrow transplantation (bmt). auto-hsct is recommended for intermediate-risk children. no prophylactic cranial irradiation is included in the protocol. patients are treated on an inpatient basis during each treatment phase.

Eligibility criteria:
inclusion criteria: * newly diagnosis of de novo acute myeloid leukemia exclusion criteria: * children with down's syndrome and acute promyelocytic leukemia, hybrid acute leukemia
kinesio taping and physiotherapeutic exercises for children with dcd

Conditions: Developmental Coordination Disorder

Summary: aim: to investigate the effectiveness of a novel elastic taping-augmented functional movement power training (kt-fmpt) program in improving leg muscular performance, body balance, motor proficiency and functional independence in children with developmental coordination disorder (dcd). methodology: in this clinical trial, twenty children with dcd (aged 6-12) will be randomly assigned to either a kt-fmpt group or a placebo control group. children in the kt-fmpt and control groups will receive elastic taping-augmented fmpt and general jogging exercise with non-elastic taping, respectively, for 12 weeks (2 hours/week). major outcome measures: body balance and leg muscle activity will be measured via muscle sensors along with a force platform. secondary outcome measures: leg muscle strength, motor proficiency and functional independence will be assessed by a digital dynamometer, the movement assessment battery for children-2 and pediatric evaluation of disability inventory, respectively (before- and after-intervention measurements). significance: the kt-fmpt group is predicted to display much better muscular and motor performances than the control group. this novel training program can be readily adopted in clinical, school, or home settings to improve functional independence in children with dcd, an outcome with positive socioeconomic implications. moreover, study findings will inspire future research work in children with other childhood-onset disabilities.


Eligibility criteria:
inclusion criteria: * 6- to 12-years-old * classified as dcd according to the diagnostic and statistical manual of mental disorders v * score \< 5th percentile on the movement assessment battery for children, 2nd edition (mabc-2) * total score \< 46 on the dcd questionnaire (2007) * attending a mainstream primary school with intelligence level within the normal range * no kt or fmpt experience exclusion criteria: * any known congenital, cognitive, psychiatric, neurological, sensorimotor, musculoskeletal or cardiopulmonary disorder that may affect test performance * receiving active rehabilitation treatment * demonstrating excessive disruptive behaviour * unable to follow instructions
transdermal hrt relieving postmenopausal symptoms

Conditions: Menopause

Summary: there is a dilemma and a permanent debate about side effects on drugs administered orally. the first-pass metabolism is related with many side effects, since the metabolites of these compounds affect the course of human physiology. conventional hormone therapy by oral route has been used for relieving menopausal symptoms. transdermal estrogens have not been used extensively in brazilian women with menopausal symptomatology, however; recently a previous long term study has indicated no increased risk breast cancer or vasomotor disorders in menopausal women, using transdermal hrt.

this was a prospective long-term clinical trial study of female patients aged 51-70 years old treated for menopause related hormone imbalances. other results of this study are published elsewhere. volunteers were recruited from referenced gynecological medical service where patient charts are maintained. this study is a prospective long-term clinical trial study randomized trial assessing the effects of transdermal hrt on climacteric symptoms and hormone serum levels in early postmenopausal women. preliminary results of this trial, including the first 42 women enrolled, have been published (3). in the present analysis, 66 women received daily in the right and left forearms a transdermal nanostructured formulation of estriol (0.1%) + estradiol (0.25%) and progesterone (10%) respectively (biolipid b2®, evidence, sp, brazil) for sixty months. the following were compared: effects of transdermal gel on baseline and after thrt were also analyzed.

Eligibility criteria:
inclusion criteria: * 1) last menstrual period between 6 months and 3 years before the beginning of the study plus follicle-stimulating hormone (fsh) levels higher than 35 iu/l; 2) age between 51 and 70 years; 3) no use of any medication known to interfere with hormonal levels in the past 6 months. exclusion criteria: * patients presenting diabetes, previous hysterectomy, endometrial thickness higher than 5 mm, history of cancer, thromboembolism or established cardio vascular disease were excluded.

Keywords: post-menopause hormone replacement therapy nanotechnology biolipid b2
glioblastoma and individualized therapies

Conditions: Glioma, Malignant

Summary: the treatment of patients with world health organization (who) grade 4 malignant glioma has not seen any significant breakthrough the past years. following surgery and radio / chemotherapy patients still experience a very high recurrence risk and the prognosis is dismal. the investigators observed patients with grade iv malignant glioma receiving individualized treatment based on their molecular profile including fully personalized vaccines.


Eligibility criteria:
inclusion criteria: * malignant glioma, idh wt exclusion criteria: * na
a study of factors that affect long-term kidney transplant function

Conditions: Kidney Transplant

Summary: the causes of deterioration of transplanted kidney function are poorly understood. the purpose of this study is to determine the disease processes that cause transplanted kidney dysfunction and loss in patients who received a kidney either recently or over a year prior to entering this study. this study will also identify specific characteristics in kidney transplant recipients that predict whether a kidney transplant will be successful.

over time, chronic kidney graft dysfunction progressively threatens the long-term survival of a kidney graft. the disease processes behind graft dysfunction are unclear. however, chronic kidney graft dysfunction is likely to be caused by certain definable factors. such factors may include collagens iii and iv, transforming growth factor (tgf)-beta, t and b cell surface markers, cell cycle proteins, fibronectin, and laminin. determining what disease processes and which specific factors are most responsible for kidney graft dysfunction may help in designing future interventional trials for kidney transplant patients. the purpose of this study is to determine whether clinical, laboratory, and histologic studies at the time of initial graft dysfunction will clarify the processes and factors that lead to deterioration and loss of a kidney graft. this is an observational study that will enroll participants who have recently received kidney transplants (prospective cohort) and participants who have had kidney transplants for a longer period of time and are now experiencing kidney graft dysfunction (retrospective cohort). the duration of this trial may differ between participants, depending on when deterioration of kidney graft function occurs. participants will be followed until graft loss or death. there are no exclusive study visits associated with this study. study data are gathered from routine laboratory follow-up tests completed at the participant's local medical center and from information obtained at the time of kidney biopsy. participants may need to undergo a kidney biopsy as clinically indicated. at the time of biopsy, participants will also undergo urine and blood collection.

Eligibility criteria:
inclusion criteria for prospective cohort: * received a kidney transplant within 10 days prior to study entry, on or after 10-01-2005 * recipient of kidney or simultaneous kidney/pancreas with no additional transplant at the time of the kidney transplant inclusion criteria for retrospective cohort: * received a kidney transplant before 10-01-2005 * recipient of kidney or simultaneous kidney/pancreas with no additional transplant at the time of the kidney transplant * undergoes a clinically indicated kidney biopsy due to new onset deterioration of function, defined as having an increase in serum creatinine * the creatinine level on or before 01-01-2006 must be 2 mg/dl or less or the patient must have developed new onset proteinuria, defined as having a protein/creatinine ratio of 0.4 or more

Keywords: kidney transplant dysfunction chronic deterioration loss of function
clinical application of mdct in coronary artery disease

Conditions: Coronary Arteriosclerosis

Summary: 1) establish normal value for coronary calcium scoring in taiwan. 2) find out the relationship of coronary calcium deposition and coronary artery stenosis. propose a clinical management guideline based on coronary calcium score. 3) evaluate sensitivity/specificity of coronary ct angiography and the influence of coronary calcium score on coronary ct angiography. 4) evaluate the clinical application of myocardial enhancement measurement.

computed tomography is evolving as a tool for noninvasive diagnosis of coronary artery disease. coronary calcium deposition amount is an established independent coronary artery disease risk factor. however, coronary artery stenosis seldom occurred in the same location as calcium deposition. with the advent of 16-detector-row multislice spiral ct, direct visualization of coronary artery is possible. but it remains a great challenge to obtain diagnostic quality image in the beating heart. small distal vessels may not be adequately visualized. artifacts from severe calcification or coronary stent may render diagnosis difficult. the clinical implication of coronary calcium score, indication of coronary ct angiography and myocardial enhancement measurement should be further studied. the purposes of this study are: 1) establish normal value for coronary calcium scoring in taiwan. 2) find out the relationship of coronary calcium deposition and coronary artery stenosis. propose a clinical management guideline based on coronary calcium score. 3) evaluate sensitivity/specificity of coronary ct angiography and the influence of coronary calcium score on coronary ct angiography. 4) evaluate the clinical application of myocardial enhancement measurement.

Eligibility criteria:
inclusion criteria: * coronary artery disease admitted for coronary angiography exclusion criteria: * heart failure, irregular heart rate
evaluation of the effectiveness of a quality improvement intervention

Conditions: Maternal and Child Health

Summary: this rigorous evaluation demonstrated that implementation of a time-limited quality improvement strategy effectively improved coverage of some components of an integrated maternal and child health service in a complex health environment, but we were unable to achieve the changes needed to provide a comprehensive package of care for mothers and children.

background: despite policies and guidelines recommending integration of health services in south africa, provision of maternal and child health services remains fragmented. this study evaluated a rapid, scaleable, quality improvement intervention to improve integration of maternal and child health and hiv services at a primary health level, in kwazulu-natal, south africa. methods: a three-month intervention comprised of six quality improvement mentoring visits, learning sessions with clinic staff to share learnings, and a self-administered checklist aimed to assist health workers monitor and implement an integrated package of health services for mothers and children. the study evaluated 27 clinics in four sub-districts using a stepped-wedge design. each sub-district received the intervention sequentially in a randomly selected order. five waves of data collection were conducted in all participating clinics between december 2016-february 2017. a multi-level, mixed effects logistic regression was used to account for random cluster fixed time and group effects using stata v13.1.

Eligibility criteria:
inclusion criteria: women who attended the clinic for maternal and child health care services at 27 participating clinics from january 2016-february 2017. exclusion criteria: women who did not attend the clinic for maternal and child health care services at 27 participating clinics from january 2016-february 2017.

Keywords: quality improvement integrated care maternal health child health hiv/aids south africa growth monitoring child growth nutrition
human leukocyte antigen (hla) mismatched unrelated allogeneic hematopoietic stem cell transplantation

Conditions: Hematologic Disease

Summary: this study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo hsct) but lack suitable donors. this project plans to use highly mismatched unrelated hla mismatched donors. ultimately, an unrelated human leukocyte antigen (hla) mismatched allo hsct transplantation plan will be established to improve the disease prognosis of this group of patients and truly enter the era of "everyone has a donor" for allo hsct.

this study is a single center, prospective, single arm exploratory clinical trial that includes patients with hematological malignancies who are indicated for allogeneic hematopoietic stem cell transplantation (allo hsct) but lack suitable donors. this project plans to use highly mismatched unrelated hla mismatched donors. ultimately, an unrelated human leukocyte antigen (hla) mismatched allo hsct transplantation plan will be established to improve the disease prognosis of this group of patients and truly enter the era of "everyone has a donor" for allo hsct.

Eligibility criteria:
inclusion criteria: * adult patients (18-60 years old) with hematological malignancies and indications for hematopoietic stem cell transplantation; * non blood donors without human leukocyte antigen (hla) high-resolution typing ≥ 9/10, or those who have difficulty finding non blood donors due to urgent medical conditions; * no suitable hla matching haploidentical donor available; * there are suitable unrelated hla mismatched (hla high-resolution typing\<9/10) donors; * the subjects or their legal representatives shall sign an informed consent form before the start of the clinical study. exclusion criteria: * patients with severe liver and kidney function (alanine aminotransferase\>2.5 times the upper limit of normal, blood creatinine\>1.5 times the upper limit of normal) and cardiopulmonary dysfunction (new york heart association (nyha) iii/iv heart function, ejection fraction\<50%, severe obstructive or restrictive ventilation dysfunction); * merge active infections; * eastern cooperative oncology group performance status (ecog) score ≥ 2 points; * secondary tumors with merged activity; * severe central nervous system or mental illness leading to the inability to autonomously choose to enter or exit clinical trials; * combine other allo hematopoietic stem cell transplantation (hsct) contraindications.

Keywords: hematopoietic cell transplantation hla mismatch hematologic diseases
allo-hsct with alternative donor in treatment of hematologic malignancy

Conditions: Acute Leukemia; Chronic Myeloid Leukemia; Myelodysplastic Syndrome

Summary: the purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-hsct) from matched sibling donor (msd),matched unrelated donor (mud) and haploidentical related donors(hrd) in the treatment of hematologic malignancy.

currently, allogeneic hematopoietic stem cell transplantation (allo-hsct) remains the only curative therapy for a majority of malignant hematologic diseases, especially acute leukemia. hsct from msd offers the best results for these diseases, but lack of this donor resource has restricted its wide application. hsct from mud provides another option, but muds still cannot satisfy all patients due to unsuccessful donor searches. almost all patients have an available related donor with whom they share a single hla haplotype (ie, haploidentical related donor), and it owns the advantage of immediate availability, especially for those who urgently need transplantation.the results of transplantation from hrd have improved significantly over the past few years. however, the results from such haploidentical transplantation have not formally been compared with those of transplantation in patients contemporaneously using msds and muds for hematologic malignancy.

Eligibility criteria:
inclusion criteria: * diagnosis of primary disease is acute leukemia/mds/cml * receiving allo-hsct exclusion criteria: * cardiac dysfunction (particularly congestive heart failure) * hepatic abnormalities (bilirubin ≥ 3 mg/dl, aminotransferase\> 2 times the upper limit of normal) * renal dysfunction (creatinine clearance rate \< 30 ml/min) * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)
effect of exercise on irisin levels of hypothyroid rats

Conditions: Hypothyroidism

Summary: the aim of study was to evaluate the role of exercise on serum irisin levels in hypothyroid rats.

contracting skeletal muscle acts as an endocrine organ, capable of secreting hormones called myokines, such as interleukin 1, interleukin 15 and irisin. myokines are important for regulation of glucose and lipid metabolism. among these, irisin, is an exercise induced polypeptide, secreted mainly by skeletal muscles and adipose tissue. irisin is also secreted in small amounts from cardiac muscle, pancreas and sebaceous glands. it is cleaved and secreted from fibronectin type iii domain-containing protein 5 (fndc5 gene) and is regulated by the peroxisome proliferator-activated receptor-γ co activator 1-α (pgc1-α) . the most important function of irisin is thermogenesis, by inducing the browning of white adipose tissue, thereby increasing energy consumption, encouraging weight loss and decreasing dietary insulin resistance. linking irisin levels with obesity, its mechanism shows that after exercise there is up regulation of a thermogenin ,an uncoupling protein-1 (ucp-1) thyroid hormone also plays an important role in glucose-lipid metabolism and energy homeostasis. hypothyroidism, a decrease in thyroid hormone levels, can lead to obesity and metabolic syndrome. it has been found that thyroid hormone is also involved in thermogenesis by inducing browning of white adipose tissue, through thyroid hormone receptors. in hypothyroidism, many metabolic processes in the body are affected such as differentiation in the adipose tissue. increased thyroid stimulating hormone (tsh) causes adipogenesis by stimulating pre-adipocyte differentiation directly through the receptors in the adipose tissue . fatty tissue is increased by adipocyte hypertrophy as a consequence of previous adipogenesis, and newly formed adipocyte-8, resulting in clinical obesity. fndc5 (fibronectin type iii domain-containing protein 5), which is the precursor of irisin, is a protein that is encoded by the fndc5 gene, is present in many tissues, including the thyroid tissue and therefore effects thyroid hormone. dysregulation of both thyroid and irisin hormones result in metabolic syndrome. the metabolic syndrome is a common metabolic disorder that has been linked to the increasing prevalence of obesity. by regulating thyroid hormone levels, irisin has a powerful impact on metabolism and thermogenesis. the association of irisin with the thyroid hormone in hypothyroidism still remains unknown and is controversial, and requires further confirmatory studies on experimental models. regular exercise is known to have significant beneficial effects on the metabolic health and this is mediated by skeletal muscle. contracting skeletal muscle is the source of irisin. studies have shown an increase in post exercise irisin levels

Eligibility criteria:
inclusion criteria: * male adult rats weighing approx. 200-250gms * 6 to 8 week old rats exclusion criteria: * female rats will be excluded. * rats with any obvious pathology * the rats weighing \>200gm

Keywords: exercise irisin hypothyroidism